Atrium Biotechnologies Inc. has announces the acquisition of the assets of London, Ontario based Douglas Laboratories Canada.

DL Canada has been marketing Douglas Laboratories products in Canada since 2000 and has current annual revenues of approximately $5 million.

"This acquisition provides Atrium with a platform to develop the Canadian healthcare professional market not only for the Douglas Laboratories brand but also for the Pure Encapsulations brand which is not currently being sold in Canada. This acquisition further reinforces our current leadership position in North America and marks another step in our strategy to control access to markets and build solid organic growth for our brands," stated Richard Bordeleau, president of Atrium's Health & Nutrition Division.

In addition, Atrium will be able to benefit from the expertise and support of DL Canada's current management and staff who are staying on to ensure the successful integration and to sustain its growth. Their operational and marketing expertise, as well as their excellent knowledge of the Canadian nutritional supplement market will be a valuable asset to Atrium.

"Our company has been focused on growing the Douglas Laboratories' business in Canada. We are convinced that under Atrium's leadership we will accelerate our growth and we are very optimistic about the future especially with the synergies created by combining our companies," concluded Dr. Victoria Coleman-Kay, President of DL Canada.